{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:37:51Z","timestamp":1793813871728,"version":"4.6.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shaanxi Provincial TCM Administration-Qinchuangyuan Initiative for Traditional Medicine Innovation","award":["2022-QCYZH-020"],"award-info":[{"award-number":["2022-QCYZH-020"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82200399"],"award-info":[{"award-number":["No.82200399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2025JC-YBMS-876"],"award-info":[{"award-number":["2025JC-YBMS-876"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2025JC-YBQN-1203"],"award-info":[{"award-number":["2025JC-YBQN-1203"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Xi'an Children's Hospital","award":["No.2022G15"],"award-info":[{"award-number":["No.2022G15"]}]},{"name":"Natural Science Foundation of Xi'an Children's Hospital","award":["No.2024D01"],"award-info":[{"award-number":["No.2024D01"]}]},{"name":"Natural Science Foundation of Xi'an Children's Hospital","award":["No.2024B02"],"award-info":[{"award-number":["No.2024B02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Pompe disease (PD), caused by a deficiency in acid \u03b1-glucosidase (GAA), is a lysosomal storage disorder. Existing Gaa knockout and point mutation mouse models have substantially advanced mechanistic understanding, but most are homozygous for single mutations and do not faithfully model the compound\u2011heterozygous GAA genotypes common in patients. A more clinically relevant in vivo model is still needed to enable systematic evaluation and faithful recapitulation of multi\u2011organ pathology. We previously reported an infantile-onset PD (IOPD) family carrying compound heterozygous\n                      <jats:italic>GAA<\/jats:italic>\n                      mutation (\n                      <jats:italic>GAA<\/jats:italic>\n                      c.1822\u00a0C\u2009&gt;\u2009T\/2662G\u2009&gt;\u2009T; R608*\/E888*). We here generated a novel compound heterozygous\n                      <jats:italic>Gaa<\/jats:italic>\n                      mouse model (\n                      <jats:italic>Gaa<\/jats:italic>\n                      c.1822\u00a0C\u2009&gt;\u2009T\/2665A\u2009&gt;\u2009T; R608*\/K889*), corresponding to human R608*\/E888*), corresponding to human\n                      <jats:italic>GAA<\/jats:italic>\n                      identified in the IOPD family.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CRISPR\/Cas9-mediated knock-in introduced R608* (exon 14) and K889* (exon 18) mutations into C57BL\/6 zygotes. Compound heterozygotes (CHet) were bred, validated via Sanger sequencing, and phenotyped using GAA activity assays, glycogen quantification, histopathology, transmission electron microscopy (TEM), and echocardiography. Parameters included cardiac structure\/function, skeletal muscle integrity, hepatic glycogenosis, and diaphragmatic pathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CHet mice exhibited reduced GAA activity and elevated plasma glycogen levels, recapitulating the metabolic hallmark of human PD. Systemic pathophysiological characterization revealed multi-organ dysfunction: the heart showed pronounced hypertrophy with structural remodeling, evidenced by thickened ventricular walls and sarcolemmal disarray, despite preserved compensatory function. Skeletal muscle pathology was marked by vacuolated myofibers, lysosomal glycogen accumulation, and mitochondrial abnormalities, reflecting impaired autophagic flux. Hepatic tissues displayed prominent glycogen storage, hepatocyte swelling, and disrupted cellular architecture. Diaphragmatic dysfunction, a critical determinant of respiratory failure in PD, was characterized by vacuolation, nuclear centralization, and inflammatory infiltration, with ultrastructural evidence of lysosomal glycogen deposition and mitochondrial damage across all tissues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      To our knowledge, this is among the first compound heterozygous\n                      <jats:italic>Gaa<\/jats:italic>\n                      mouse models integrating East Asian-specific\n                      <jats:italic>GAA<\/jats:italic>\n                      mutations (R608*\/E888*) and demonstrating multi-organ pathophysiology similar to human PD. By preserving residual GAA activity (~\u200918%) and recapitulating cardiac, skeletal, hepatic, and respiratory defects, our model provides an important complementary platform for elucidating mutation-specific mechanisms, optimizing enzyme replacement therapy (ERT), and advancing gene-editing strategies. Its alignment with patient-derived iPSC findings enhances the translational relevance of research in PD and lysosomal disorders.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04273-x","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:47:17Z","timestamp":1771994837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Generation and characterization of a novel Gaa compound heterozygous mouse model recapitulating human Pompe disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Wenjun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7638-1442","authenticated-orcid":false,"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"4273_CR1","doi-asserted-by":"crossref","unstructured":"Hannah WB, Derks TGJ, Drumm ML, Gr\u00fcnert SC, Kishnani PS, Vissing J. Glycogen storage diseases. Nat Rev Dis Primers. 2021;9(1).","DOI":"10.1038\/s41572-023-00456-z"},{"key":"4273_CR2","doi-asserted-by":"crossref","unstructured":"Kishnani PS, Gibson JB, Gambello MJ, Hillman R, Stockton DW, Kronn D, et al. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease. Genet Med. 2019;21(11).","DOI":"10.1038\/s41436-019-0527-9"},{"key":"4273_CR3","doi-asserted-by":"crossref","unstructured":"van der Beek NAME, Theunissen MTM, van den Hout JMP, Pijnappel WWM, Schoser B, Lafor\u00eat P, et al. Clinical insights in enzyme replacement therapy for metabolic storage disorders: lessons from Pompe disease. Lancet Neurol. 2025;24(3).","DOI":"10.1016\/S1474-4422(24)00518-0"},{"key":"4273_CR4","doi-asserted-by":"crossref","unstructured":"Taverna S, Cammarata G, Colomba P, Sciarrino S, Zizzo C, Francofonte D, et al. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging. 2020;12(15).","DOI":"10.18632\/aging.103794"},{"key":"4273_CR5","doi-asserted-by":"crossref","unstructured":"Kan SH, Huang JY, Harb J, Rha A, Dalton ND, Christensen C, et al. CRISPR-mediated generation and characterization of a Gaa homozygous c.1935C\u2009>\u2009a (p.D645E) Pompe disease knock-in mouse model recapitulating human infantile onset-Pompe disease. Sci Rep. 2020;12(1).","DOI":"10.1038\/s41598-022-25914-8"},{"key":"4273_CR6","doi-asserted-by":"crossref","unstructured":"Huang JY, Kan SH, Sandfeld EK, Dalton ND, Rangel AD, Chan Y, et al. CRISPR-Cas9 generated Pompe knock-in murine model exhibits early-onset hypertrophic cardiomyopathy and skeletal muscle weakness. Sci Rep. 2020;10(1).","DOI":"10.1038\/s41598-020-65259-8"},{"key":"4273_CR7","first-page":"100734","volume":"27","author":"KY Park","year":"2021","unstructured":"Park KY, Li S, McNeil A, Choi Y, Lee J, Kim D, et al. Carrier frequency and predicted genetic prevalence of Pompe disease based on a large-scale, ethnically diverse population dataset. Mol Genet Metab Rep. 2021;27:100734.","journal-title":"Mol Genet Metab Rep"},{"key":"4273_CR8","unstructured":"Huang JY, Kan SH, Sandfeld EK, Dalton ND, Rangel AD, Chan Y, et al. Mol Genet Metab. 2011;103(1):1\u201311."},{"key":"4273_CR9","doi-asserted-by":"publisher","first-page":"1061384","DOI":"10.3389\/fcvm.2022.1061384","volume":"9","author":"W Huang","year":"2022","unstructured":"Huang W, Zhang Y, Zhou R. Induced pluripotent stem cell for modeling Pompe disease. Front Cardiovasc Med. 2022;9:1061384.","journal-title":"Front Cardiovasc Med"},{"key":"4273_CR10","doi-asserted-by":"crossref","unstructured":"Kiraly S, Stanley J, Eden ER. Lysosome-mitochondrial crosstalk in cellular stress and disease. Antioxidants. 2025;14(2).","DOI":"10.3390\/antiox14020125"},{"key":"4273_CR11","doi-asserted-by":"publisher","first-page":"101621","DOI":"10.1016\/j.scr.2019.101621","volume":"41","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Li A, Wang J, Wang G, Wang D. Generation of induced pluripotent stem cells (iPSCs) from an infant with Pompe disease carrying with compound mutations of R608X and E888X in GAA gene. Stem Cell Res. 2019;41:101621.","journal-title":"Stem Cell Res"},{"key":"4273_CR12","doi-asserted-by":"publisher","first-page":"102934","DOI":"10.1016\/j.scr.2022.102934","volume":"64","author":"W Huang","year":"2020","unstructured":"Huang W, Zhou Y, Wang J, Jiang C, Zhang Y, Zhou R. Generation of two heterozygous GAA mutation-carrying human induced pluripotent stem cell lines (XACHi005-A, XACHi006-A) from parents of an infant with Pompe disease. Stem Cell Res. 2020;64:102934.","journal-title":"Stem Cell Res"},{"key":"4273_CR13","doi-asserted-by":"crossref","unstructured":"Huang W, Zhou R, Jiang C, Wang J, Zhou Y, Xu X, et al. Mitochondrial dysfunction is associated with hypertrophic cardiomyopathy in Pompe disease-specific induced pluripotent stem cell-derived cardiomyocytes. Cell Prolif. 2024;57(4).","DOI":"10.1111\/cpr.13573"},{"key":"4273_CR14","first-page":"117978","volume":"185","author":"RC Gaspar","year":"2025","unstructured":"Gaspar RC, Sakuma I, Nasiri A, Hubbard BT, LaMoia TE, Leitner BP, et al. Small molecule Inhibition of glycogen synthase I reduces muscle glycogen content and improves biomarkers in a mouse model of Pompe disease. Am J Physiol Endocrinol Metab. 2025;185:117978.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4273_CR15","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1093\/hmg\/ddz133","volume":"28","author":"PS Kishnani","year":"2019","unstructured":"Kishnani PS, Sun B, Koeberl DD. Gene therapy for glycogen storage diseases. Hum Mol Genet. 2019;28:R1.","journal-title":"Hum Mol Genet"},{"key":"4273_CR16","unstructured":"Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature. 2024;625(7993)."},{"key":"4273_CR17","doi-asserted-by":"crossref","unstructured":"Chen X, Liu T, Huang M, Wu J, Zhu J, Guo Y, et al. Clinical and molecular characterization of infantile-onset Pompe disease in mainland Chinese patients: identification of two common mutations. Genet Test Mol Biomarkers. 2017;21(6).","DOI":"10.1089\/gtmb.2016.0424"},{"key":"4273_CR18","unstructured":"Karapurkar JK, Antao AM, Kim KS, Ramakrishna S. CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals. Am J Physiol Endocrinol Metab. 2024;327(4)."},{"key":"4273_CR19","doi-asserted-by":"crossref","unstructured":"Fusco AF, McCall AL, Dhindsa JS, Zheng L, Bailey A, Kahn AF, et al. The respiratory phenotype of Pompe disease mouse models. Int J Mol Sci. 2020;21(6).","DOI":"10.3390\/ijms21062256"},{"key":"4273_CR20","doi-asserted-by":"crossref","unstructured":"Falk DJ, Mah CS, Soustek MS, Lee KZ, Elmallah MK, Cloutier DA, et al. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Mol Ther. 2013;21(9).","DOI":"10.1038\/mt.2013.96"},{"key":"4273_CR21","doi-asserted-by":"crossref","unstructured":"Deus CM, Yambire KF, Oliveira PJ, Raimundo N. Mitochondria-lysosome crosstalk: from physiology to neurodegeneration. Trends Mol Med. 2020;26(1).","DOI":"10.1016\/j.molmed.2019.10.009"},{"key":"4273_CR22","doi-asserted-by":"crossref","unstructured":"Molares-Vila A, Corbal\u00e1n-Rivas A, Carnero-Gregorio M, Gonz\u00e1lez-Cesp\u00f3n JL. Rodr\u00edguez-Cerdeira C. Biomarkers in glycogen storage diseases: an update. Int J Mol Sci. 2021;22(9).","DOI":"10.3390\/ijms22094381"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04273-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04273-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04273-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:49:54Z","timestamp":1781635794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04273-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4273"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04273-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were approved by the Ethics Committee of Xi\u2019an Children\u2019s Hospital and conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained for research and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}